297 related articles for article (PubMed ID: 26049666)
1. [Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis].
Berlanga A; Guiu-Jurado E; Porras JA; Aragonès G; Auguet T
Clin Investig Arterioscler; 2016; 28(1):47-61. PubMed ID: 26049666
[TBL] [Abstract][Full Text] [Related]
2. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD.
Fuchs CD; Claudel T; Trauner M
Trends Endocrinol Metab; 2014 Nov; 25(11):576-85. PubMed ID: 25183341
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathways in non-alcoholic fatty liver disease.
Berlanga A; Guiu-Jurado E; Porras JA; Auguet T
Clin Exp Gastroenterol; 2014; 7():221-39. PubMed ID: 25045276
[TBL] [Abstract][Full Text] [Related]
5. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
Schuppan D; Schattenberg JM
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and non-alcoholic fatty liver disease.
Woods CP; Hazlehurst JM; Tomlinson JW
J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
[TBL] [Abstract][Full Text] [Related]
9. Deciphering non-alcoholic fatty liver disease through metabolomics.
Cano A; Alonso C
Biochem Soc Trans; 2014 Oct; 42(5):1447-52. PubMed ID: 25233430
[TBL] [Abstract][Full Text] [Related]
10. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
Pár A; Pár G
Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease.
Smith BW; Adams LA
Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways of nonalcoholic fatty liver disease development and progression.
Bessone F; Razori MV; Roma MG
Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.
Brea Á; Pintó X; Ascaso JF; Blasco M; Díaz Á; González-Santos P; Hernández Mijares A; Mantilla T; Millán J; Pedro-Botet J;
Clin Investig Arterioscler; 2017; 29(3):141-148. PubMed ID: 27692633
[TBL] [Abstract][Full Text] [Related]
14. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
Yan Z; Miao X; Zhang B; Xie J
Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
[TBL] [Abstract][Full Text] [Related]
15. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
16. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis.
van der Graaff D; Kwanten WJ; Francque SM
Med Hypotheses; 2019 Jan; 122():188-197. PubMed ID: 30593409
[TBL] [Abstract][Full Text] [Related]
17. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic steatohepatitis: new insights from OMICS studies.
Martel C; Esposti DD; Bouchet A; Brenner C; Lemoine A
Curr Pharm Biotechnol; 2012 Apr; 13(5):726-35. PubMed ID: 22122481
[TBL] [Abstract][Full Text] [Related]
19. Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.
Lim JW; Dillon J; Miller M
World J Gastroenterol; 2014 Jul; 20(26):8325-40. PubMed ID: 25024592
[TBL] [Abstract][Full Text] [Related]
20. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.
Cusi K
Clin Liver Dis; 2009 Nov; 13(4):545-63. PubMed ID: 19818304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
